<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222725</url>
  </required_header>
  <id_info>
    <org_study_id>Tarsius 2020</org_study_id>
    <secondary_id>2019-004327-20</secondary_id>
    <secondary_id>Grant Agreement Number 879598</secondary_id>
    <nct_id>NCT04222725</nct_id>
  </id_info>
  <brief_title>A Study of TRS01 in Participants With Post-surgical Ocular Inflammation</brief_title>
  <official_title>A Multicenter, Double-Masked, Randomized, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety of TRS01 Eye Drops in Participants With Post-surgical Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tarsius Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tarsius Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye
      drops as compared to placebo on participants with ocular inflammation after cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of both systemic and ocular adverse events</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post Surgical Ocular Inflammation</condition>
  <arm_group>
    <arm_group_label>TRS01 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TRS01 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TRS01 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRS01 eye drops</intervention_name>
    <description>Dosed 4 times a day (QID)</description>
    <arm_group_label>TRS01 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRS01 eye drops</intervention_name>
    <description>Dosed QID</description>
    <arm_group_label>TRS01 medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRS01 eye drops</intervention_name>
    <description>Dosed QID</description>
    <arm_group_label>TRS01 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo eye drops</intervention_name>
    <description>Dosed QID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pre-operatively, individuals of either gender or any race will be eligible for study
        participation if they are:

          -  18 years of age or older.

          -  Able to provide informed consent, follow instructions and complete all required study
             visits for the duration of the study.

          -  Scheduled for routine cataract surgery (phacoemulsification or extracapsular
             extraction) with posterior chamber intraocular lens (IOL) implantation, and not
             combined with any other surgery.

          -  Have vision â‰¥ 20/200 in the non-study eye.

          -  Able to self-administer eye drops (tested during screening by self-administration of
             &quot;artificial tears&quot;), or have a care provider that can administer the drops.

          -  Have no known sensitivity /allergy to the TRS01 or formulation excipients.

          -  Using adequate birth control by men and women, if of reproductive potential and
             sexually active, as specified per protocol

          -  Randomization inclusion criteria as specified per protocol.

        Exclusion Criteria:

          -  Scheduled to undergo cataract surgery in the non-study eye for the duration of the
             study.

          -  Receiving specific medication/interventions as specified per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inglewood</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siobhan Garbutt</last_name>
      <phone>919-595-0258</phone>
      <email>siobhan.garbutt@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petaluma</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siobhan Garbutt</last_name>
      <phone>919-595-0258</phone>
      <email>siobhan.garbutt@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington, MO</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siobhan Garbutt</last_name>
      <phone>919-595-0258</phone>
      <email>Siobhan.Garbutt@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siobhan Garbutt</last_name>
      <phone>919-595-0258</phone>
      <email>Siobhan.Garbutt@lexitas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siobhan Garbutt</last_name>
      <phone>919-595-0258</phone>
      <email>siobhan.garbutt@lexitas.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative</keyword>
  <keyword>postsurgical</keyword>
  <keyword>ocular</keyword>
  <keyword>inflammation</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

